AFP and hepatocellular carcinoma: The performance of CircPanel vs. AFP was AUC 0.863 vs. 0.790 (p=0.036) in the training set (53 healthy controls, 52 with CHB, 50 with liver cirrhosis and 158 with HCC), AUC 0.843 vs. 0.747 (p=0.011) in Validation Set 1 (152 HCC patients, 50 healthy controls, 54 CHB patients and 50 HBV-induced liver cirrhosis patients), and AUC 0.864 vs. 0.769 (p<0.001) in Validation Set 2 (290 HCC patients, 76 healthy controls, 80 CHB patients and 80 HBV-induced liver cirrhosis patients) (54).